
Quarterly report 2025-Q2
added 08-04-2025
Glaukos Corporation Net Debt 2011-2026 | GKOS
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Glaukos Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.6 M | -46.9 M | -27 M | 94 M | 10.2 M | -29.8 M | -24.5 M | -6.49 M | -11.9 M | 17 M | 10.8 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 94 M | -46.9 M | -3.29 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical instruments industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
-45 M | - | - | $ 810 M | ||
|
Luminex Corporation
LMNX
|
-106 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-517 K | - | -9.52 % | $ 20.6 M | ||
|
Alcon
ALC
|
2.46 B | $ 75.4 | -0.8 % | $ 40.4 B | ||
|
Ekso Bionics Holdings
EKSO
|
-581 K | $ 11.21 | -1.41 % | $ 27.2 M | ||
|
The Cooper Companies
COO
|
2.38 B | $ 63.09 | -1.94 % | $ 12.6 B | ||
|
Antares Pharma, Inc.
ATRS
|
-12.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
781 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
66.8 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
1.58 B | - | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
-411 M | - | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
972 M | $ 121.01 | -1.5 % | $ 2.98 B | ||
|
iRhythm Technologies
IRTC
|
-154 M | $ 125.44 | -0.41 % | $ 4.01 B | ||
|
Haemonetics Corporation
HAE
|
623 M | $ 59.84 | -1.06 % | $ 3.01 B | ||
|
electroCore
ECOR
|
-53 K | $ 6.15 | 1.32 % | $ 52.2 K | ||
|
Repro Med Systems
KRMD
|
-8.38 M | $ 4.08 | 0.49 % | $ 188 M | ||
|
Isoray
ISR
|
-28.4 M | - | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
-3.2 B | $ 466.64 | -0.92 % | $ 167 B | ||
|
Microbot Medical
MBOT
|
-3.05 M | $ 2.1 | -3.23 % | $ 96.2 M | ||
|
Milestone Scientific
MLSS
|
-955 K | $ 0.33 | -4.15 % | $ 27.1 M | ||
|
Masimo Corporation
MASI
|
572 M | $ 178.51 | -0.08 % | $ 9.51 B | ||
|
InfuSystem Holdings
INFU
|
33.3 M | $ 10.18 | -4.5 % | $ 210 M | ||
|
Merit Medical Systems
MMSI
|
299 M | $ 66.74 | -1.02 % | $ 3.95 B | ||
|
Envista Holdings Corporation
NVST
|
276 M | $ 26.49 | -1.05 % | $ 4.45 B | ||
|
Pulse Biosciences
PLSE
|
-73.2 M | $ 21.83 | -3.62 % | $ 1.47 B | ||
|
Retractable Technologies
RVP
|
-1.69 M | $ 0.62 | -2.99 % | $ 18.6 M | ||
|
Pro-Dex
PDEX
|
15 M | $ 51.51 | -0.87 % | $ 169 M | ||
|
LeMaitre Vascular
LMAT
|
143 M | $ 112.4 | -1.85 % | $ 2.54 B | ||
|
STAAR Surgical Company
STAA
|
-115 M | $ 26.7 | 0.07 % | $ 1.32 B | ||
|
STERIS plc
STE
|
1.78 B | $ 219.75 | -1.1 % | $ 21.7 B | ||
|
Predictive Oncology
POAI
|
-9.23 M | - | - | $ 31.1 M | ||
|
Teleflex Incorporated
TFX
|
2.26 B | $ 135.52 | 0.33 % | $ 6.05 B | ||
|
BioLife Solutions
BLFS
|
-88.9 M | $ 20.9 | -2.38 % | $ 963 M | ||
|
Stereotaxis
STXS
|
-7.98 M | $ 1.86 | -3.63 % | $ 169 M | ||
|
Baxter International
BAX
|
7.55 B | $ 17.94 | -2.97 % | $ 9.2 B | ||
|
ResMed
RMD
|
513 M | $ 217.14 | -2.2 % | $ 31.7 B | ||
|
AtriCure
ATRC
|
-104 M | $ 28.48 | -1.93 % | $ 1.36 B | ||
|
Utah Medical Products
UTMD
|
-60.6 M | $ 66.61 | -0.25 % | $ 216 M | ||
|
Harvard Bioscience
HBIO
|
27.8 M | $ 6.45 | -5.56 % | $ 286 M | ||
|
NeuroMetrix
NURO
|
-1.49 M | - | 5.05 % | $ 9.02 M | ||
|
West Pharmaceutical Services
WST
|
-566 M | $ 292.13 | -3.33 % | $ 21.1 B | ||
|
DENTSPLY SIRONA
XRAY
|
1.74 B | $ 11.78 | -1.51 % | $ 2.35 B | ||
|
AngioDynamics
ANGO
|
-48.3 M | $ 10.98 | -0.99 % | $ 449 M | ||
|
Becton, Dickinson and Company
BDX
|
17.1 B | $ 149.52 | -0.47 % | $ 43 B | ||
|
Nephros
NEPH
|
-2.48 M | $ 3.32 | 2.79 % | $ 34.5 M | ||
|
OraSure Technologies
OSUR
|
-197 M | $ 3.01 | - | $ 221 M | ||
|
Repligen Corporation
RGEN
|
-236 M | $ 117.43 | -0.73 % | $ 6.54 M |